Monday, 8 June 2020

Global Gene Expression Analysis Market Growth Factors, Types And Application By Regional Analysis 2023

Market Scenario:
Gene expression analysis is research dedicated towards functional genomics extending the application purview of studying genes and gene transcripts. Synthesizing functional gene products such as functional RNAs and protein species offers insights on how an intact organism survives when a particular gene goes missing. Growth in personalized medicine and technological developments are driving market growth. According to a data published by the Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicines in 2017. Moreover, the development of genomic databases and increased government funding towards genomics is fueling market growth.
However, the lack of skilled labor and the high cost of instruments may hamper market growth during the assessment period.
The Global Gene Expression Analysis Market Size is expected to grow significantly over the forecast period. It is estimated that the global gene expression analysis market is expected to hold a market value of USD 3.250 million and register a CAGR ~9.1% during the forecast period of 2018 to 2023.
Segmentation
The global gene expression analysis market has been segmented into product, services, application, end-user, and region.
The market, on the basis of product, has been segmented into consumables and instruments.
The market, based on consumables, has been further segmented into reagents and DNA chips.
The market, based on instruments, has been further segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others.
The market, by services, has been segmented into gene expression profiling services, sequencing services, bioinformatics solutions, and others.
The market, by application, has been segmented into drug discovery, diagnosis, research, and others.
The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gene expression analysis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gene expression analysis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The gene expression analysis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gene expression analysis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Some of the key players in the global gene expression analysis market are GENERAL ELECTRIC COMPANY, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pacific Biosciences of California, Inc., BGI, PerkinElmer Inc., Agilent Technologies, Inc., QIAGEN, Oxford Gene Technology, Eurofins Scientific, Danaher, Genotypic Technology Pvt Ltd, Macrogen Inc.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global gene expression analysis market owing to the increasing research activities and the rising popularity of gene expression tests. Additionally, the well-developed healthcare sector is anticipated to boost the American gene expression analysis market.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing investment from governments in the field of genomics, and continuously developing economies. According to a report published by the International Journal of Social and Developmental Concerns in October 2017, in Malaysia, the growth of the public primary, as well as secondary care facilities, has decreased in the past few years, and it has not kept pace with the rapid urbanization. Thus, such factors restraint the growth of the market in this region. On the other hand, the Middle East & Africa has the least share of the market.
Europe is expected to hold the second largest position in the global gene expression analysis market. The market growth in this region is attributed to the availability of funds for research.
Posted by at No comments:

Worldwide Leukemia Therapeutics Market Witness A Remarkable Growth Projected By 2023

Leukemia Therapeutics Market Scenario:
The clinical condition an in which an increased number of abnormal leucocytes or generally called white blood cells of malignant characteristic is called leukemia. Frequent infections, fever with chills and fatigue are early signs of leukemia. Acute, chronic, lymphocytic, and myelogenous leukemias are classified under leukemia. Cancer statistics center of American Cancer Society estimates 61780 new cases of leukemia in 2019. Treatment for such a malicious disease requires intense therapeutic attention. Therefore, the need for accurate treatment in the rising population of leukemia patients is the major factor impelling the global leukemia therapeutics market growth. The traditional therapies involved in the treatment of leukemia are chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The complex pathology of leukemia demands advancements in medical infrastructure for treatment. Hence, letting the market key players immense opportunity to invest in research and development and bring forth innovation in the leukemia therapy. This generates a lead for clinical researchers to investigate better drug administration methods. Efforts which are being made to deliver more effective leukemia therapies is likely to trigger the leukemia therapeutics industry market growth.
However, on the flip side, the high cost of existing leukemia therapies and investment required for developing new therapies is curbing the expansion of leukemia therapeutics market share.
Global leukemia therapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held the value of USD 10.7 billion in 2017 and is projected to grow at a CAGR of 5.3% during the assessment period predicts Market Research Future (MRFR).
Segmentation
The global leukemia therapeutics market has been segmented into type, applications, and region.
Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others. The acute lymphocytic leukemia segment is expected to account for the largest share segment of the market in 2017.
Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.
Top Key Players
  • Eisai Co., Ltd (Japan)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Bristol-Myers Squibb Company (US)
  • Hoffmann-La Roche AG (Switzerland)
  • Sanofi S.A. (France)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Amgen Inc (US)
  • Takeda Pharmaceutical Company Ltd (Japan)
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.
Europe is expected to hold the second largest position in the global leukemia therapeutics market. The market growth in this region is attributed to increase prevalence of leukemia.
The leukemia therapeutics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.
The Middle East & Africa has the least share of the leukemia therapeutics market.
Posted by at No comments:

Plasma Fractionation Market Expects An Extensive Growth In Roi Till 2023

Plasma Fractionation Market Scenario:
Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
Rising participation of market players is one of the key factors driving the plasma fractionation market. For instance, in 2018, Grifols acquired 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp. for USD 286 million. With this acquisition, Grifols now owns 249 plasma donation centres to increase its supply of plasma proteins used for therapeutic purposes.
In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.
Global Plasma Fractionation Market Growth expected to rise significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.
Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.
However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.
Segmentation
The global plasma fractionation market is segmented based on product, application, end user, and region.
The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.
Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.
Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.
In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.
On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.
Posted by at No comments:

Cerebrospinal Fluid Management (CSF) Devices Market By Key Vendors, Regions, Trends with Industry Study & Forecast to 2023

Market scenario
Rising cases of hydrocephalus is one of the key factors driving the cerebrospinal fluid management (CSF) devices market. According to the Brain Foundation, one in every 1,000 Australian children is born with hydrocephalus annually.
Global cerebrospinal fluid management (CSF) devices market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 4.5% over the forecast period.
Various other factors such as rising research & development expenditure, geriatric population, technological advancements, growing adoption of minimally invasive procedures, and rising awareness about hydrocephalus are also expected to propel the growth of the market.
However, lack of trained professionals, side-effects associated with the treatment, and high cost of devices can hinder the market growth over the forecast period.
Key players
Medtronic plc, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, DePuy Synthes, Spiegelberg GmbH & Co. KG, SOPHYSA, Natus Medical Incorporated, Dispomedica GmbH, Delta Surgical Limited, Argi Grup, Moller Medical GmbH, G. SURGIWEAR LTD., Wellong Instruments Co., Ltd., BeckerSmith Medical, Inc., and others.
Segmentation
The Global cerebrospinal fluid management (CSF) devices market is segmented based on product, age group, end user, and region.
The Global market for cerebrospinal fluid management (CSF) devices, by product is segmented into shunts, valve, and external drainage systems.
The shunts segment is further classified as ventriculoperitoneal (VP), ventriculoatrial (VA), lumboperitoneal (LP), and ventriculopleural (VPL). The valve segment is further classified as fixed, and adjustable. The external drainage systems segment is further classified as external ventricular drainage (EVD) systems, and lumbar drainage (LD) systems.
Based on age group, the market is segmented into paediatric, adult, and geriatric.
Based on end user, the market is segmented into hospitals, ambulatory settings, clinics, research and academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The cerebrospinal fluid management (CSF) devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cerebrospinal fluid management (CSF) devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cerebrospinal fluid management (CSF) devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebrospinal fluid management (CSF) devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for cerebrospinal fluid management (CSF) devices owing to the rising geriatric population and presence of major market players. As per the 2018 statistics suggested by the U.S. Census Bureau, by 2035, there will be 78 million people 65 years and older compared to 76 million under the age of 18.
In 2017, it was estimated that Europe stood second in the global cerebrospinal fluid management (CSF) devices market. This can be attributed to the rising research and development investments and increasing technological advancements.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure and rising cases of hydrocephalus drives the regional markets of the Asia Pacific region. According to the Hydrocephalus association, approximately 200,000 cases of congenital hydrocephalus in infants are registered around the world. However, in India, nearly 12,000 cases of congenital hydrocephalus are registered each year.
On the other hand, the Middle East and Africa held least cerebrospinal fluid management (CSF) devices market share in global market due to the low per capita income and stringent government policies, especially within the African region.
Posted by at No comments:

2020 Latest Study explores the Biochips Market Witness Highest Growth in near future by 2023

Market Scenario

Global biochips market is expected to grow significantly over the forecast period. The market held a market value of USD 7,300 million in 2017 and is projected to grow at a CAGR of 16.6% over the forecast period. Biochips are intended to function in biological environment, preferably inside living organism.
The factors such as increasing technological advancements in biochips is the major driving factor for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer genomics. Furthermore, growing applications of biochips will boost the market growth during forecast period. For instance, biochips can perform thousands of biological reactions operations in few seconds.  
However, high cost of the instruments and stringent regulatory guidelines may restrain the growth of the market.
According to national Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
 Segmentation
The global biochips market has been segmented into type, technology, and end user.
By type, the market has been segmented into DNA chips, lab-on-a-chip, protein chips, cell arrays, and tissue arrays. DNA chips is further segmented into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, drug discovery, agricultural biotechnology, and others. Lab-on-a-chip is further segmented into clinical diagnostics, genomics, IVD (In-Vitro Diagnostic) & POC (Point of care), Proteomics, Drug Discovery, and others. Protein chips is further segmented into proteomics, expression profiling, diagnostics, high-throughput screening, drug discovery, others.
Based on technology, the market has been segmented into microarrays and microfluidics.
The biochips market, by end user, has been segmented into biotechnology and pharmaceutical companies, hospitals and diagnostics centers, academic & research institutes, and others.
The global biochips market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biochips market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.     
The European biochips market has been segmented into Western Europe and Eastern Europe. The Western Europe biochips market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.      
The biochips market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biochips market in the Middle East & Africa has been segmented into the Middle East and Africa.      
Key players
Perkinelmer, Inc., Fluidigm Corporation, Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid Inc., Illumina, Inc., GE Healthcare, Thermo Fisher Scientific, Inc, Roche Diagnostics are some of the prominent players in the global biochips market.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global biochips market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the global biochips market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The biochips market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biomedical and biotechnology sector and growing number of target population in the region. 
The Middle East & Africa has the lowest share of the global biochips market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector. 
Posted by at No comments:

Surgical Drills Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 - 2023

Market Scenario:
Global Surgical Drills Market Research Report: by Product (pneumatic drills, electric drills, and others), By Application (orthopedic surgery, neurosurgery, dental surgery, and others) By End-user (Hospitals & clinics, and others) -Forecast Till 2023
An expert on premium research reports, Market Research Future asserts that the, Global Surgical Drills Market is expected to grow significantly over the forecast period. The market held a market value of USD 463.64 million in 2017 and is projected to grow at a CAGR of 4.93% over the forecast period.
Surgical drills as the name itself suggests, are drill machines which are used during the various surgical procedures. Their main function is to drill, cut, and bore holes in the bone in order to attach surgical pins, plates, or screws. There are several types of surgical drills available which are powered by different source. These include pneumatic drills, electric drills, and battery powered drills among others. Surgical drills have simplified the tedious job of a surgeon and reduced the surgery time significantly. Surgical drills have become an important tool in the surgical procedures. Due to high surgical drills market demand and Increasing number of orthopedic and dental surgeries, high awareness about the dental hygiene and high disposable income are some of the factors contribute to the growth of the surgical drills market share.
Key players:
Adeor medical AG, AlloTech Co.Ltd. Arthrex Inc., B.Braun Melsungen AG, CONMED Corporation, De Soutter Medical, DePuy Synthes, Medtronic plc, Stryker Corporation and Zimmer Biomet Holdings, Inc. are some of the key players in the global surgical drills market.
Segmentation:The Global Surgical Drills Market has been segmented into product, application and end-user.Based on products, the market has been segmented into, pneumatic drills, electric drills, battery powered drills, accessories, and others. The pneumatic drills segment is expected to account for the largest share in the global surgical drills market in 2017. This large share is majorly attributed to the wider acceptance of the devices, and better patient compliance as compared to other products. Based on application, the market has been segmented into orthopedic surgery, neurosurgery, ENT, dental surgery, and other. The orthopedic surgery segment is expected to account for the largest share in the global surgical drills market in 2017 followed by dental surgery segment.Based on end-users, the market has been segmented into hospitals & clinics, ambulatory surgical centers, academic and research institutes, and others. The hospitals & clinics segment is expected to account for the largest share in the global surgical drills market in 2017. At the same time, the increasing establishments of the ambulatory surgical centers in the developed and developing countries has led this segment to grow at the fastest rate during the forecast period.
Based on the regions, the market for surgical drills is segmented in to, the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The surgical drills market in the Americas region has further been segmented into North America and South America, where-in the North American market is further divided into the US and Canada.European surgical drills market has been segmented into Western Europe and Eastern Europe where-in Western Europe region is further divided into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The surgical drills market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The surgical drills market in the Middle East & Africa has been segmented into regions such as the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global surgical drills market owing to the rising number of the orthopaedic surgeries, increasing awareness about dental hygiene leading to increase in dental procedures and surgeries. The development of the better surgical approaches and advanced treatment procedures have affected the growth of the American market in a positive way. Moreover, high awareness among American population, state of the art medical infrastructure, high disposable income, are some of the many factors that drive the growth of the surgical drills market in this region.
Europe is expected to hold the second largest market share in the global surgical drills market. The market growth in this region is majorly attributed to the increasing government support for the device manufacturers. Geographical expansion of companies has led to the wider reach of the medical products and services which has brought a huge change in terms of the acceptance and implementation of the new products as well as procedures. Similarly, Asia-Pacific region has observed a rapid growth in the surgical drills market owing to the development in the medical sector in developing countries like India and China. Moreover, increase in government funding for healthcare, rising R&D expenditure, and growing number of medical device companies in the region has led to its fastest growth during the forecast period. The Middle East & Africa region is anticipated to show minor growth opportunities in the surgical drills market during the forecast period.
Posted by at No comments:

Animal Genetics Market Growth Analysis, Industry Trends, and Forecast by 2023

Market Scenario:
Animal genetics is a branch of genetics that pacts with the study of genetic variation and inheritance, primarily for domestic and wild animals. The Animal Genetics Market is expected to witness tremendous growth owing to as increased adoption of genetic services to prevent genetic diseases and business loss, and rising acceptance of advanced genetic technologies. Other key factors such significant investments in R&D and expansions undertaken by key players are contributing towards the growth of the market. However, challenges such as need for specific breeding programs for breeds with inferior economic performance, and economic sustainability in local breeds is likely to curb the market growth during the forecast period.
For the commercial level, animal genetics is used for services such as DNA typing, genetic disease testing, and genetic trait testing. This methodology uses hybrid population, ontogenetic, and cytological studies for determining the genetic hybridizations. For instance, a genetically modified cow might be able to produce more milk and can be less prone to common cattle diseases, such as clostridial disease, bovine respiratory disease complex, etc., thus, effectively increasing overall profit of the cattle farmers.
The Global Animal Genetics Market size is projected to register a CAGR of 8.4% over the forecast period.
The key factor responsible for influencing this market is increasing consumption of animal-derived protein, growing global population and rapid urbanization, and growing focus on identifying superior breeds have aided the growth of the toxicology testing market. However, factors such as, the high cost of animal testing, stringent regulatory framework for genetic engineering, and lack of skilled professionals and are expected to restrict the market growth during the forecast period.
Key players:
  • Neogen Corporation (US),
  • Genus (UK),
  • URUS (US),
  • EW Group (Germany),
  • Groupe Grimaud (France),
  • CRV Holding B.V. (The Netherland),
  • Topigs Norsvin (Netherlands),
  • Zoetis (US),
  • Envigo (US)
  • Hendrix Genetics BV (The Netherland),
  • Animal Genetics (US),
  • Alta Genetics (US),
  • vetGen (US)
Segmentation:The Animal Genetics Market Global is segmented into animal genetic products, services, and end-user. The Animal Genetics Market, by animal genetic products, the market is segmented into genetic materials and live animals. The live animals are further bifurcated into poultry, bovine, porcine, canine and others. The genetic materials are sub-segmented into semen and embryo. On the basis of services, the animal genetics market is bifurcated into genetic disease tests, DNA typing, gene trait tests, and others. On the basis of end-user, the market is segmented into veterinary hospitals & clinics, diagnostic centers, research centers and institutes, and others
Regional Market Summary 
The Americas is the largest in the market owing to the high acceptance of animal genetics in research, the development in research expenditure along with the increasing acquisition by the market players are also accountable for the growth of the animal genetics market. For instance, in 2018, Neogen completed the acquisition of Livestock Genetic Services, a firm that specializes in genetic evaluations and data management for cattle-breeding organizations. This strategy enhances the company’s in-house genetic evaluation capabilities and further expands the company’s global network of animal genomics laboratories.
The European region is the second largest animal genetics market over the forecast period due to high consciousness about animal wellbeing coupled with increased expenditure on veterinary services in the region. As per a report by the European Pet Food Industry Federation, more than 75 million households in Europe own a pet.
The Asia Pacific region is likely to develop at the uppermost CAGR for the animal genetics market in the years to come. Moreover, the rising veterinary care services both at the veterinary hospital and at community level are expected to influence the market in a positive way.
The Middle East and Africa accounts for the least share due to low per capita income and lack of availability of well-trained healthcare professionals. However, there has been an increasing demand for test accuracy and consistency among end-users and the government in this region that is enhancing the adoption of animal genetic technology in this region.

Browse More Report Details @ https://www.marketresearchfuture.com/reports/animal-genetics-market-7004 
Posted by at No comments:
Subscribe to: Posts (Atom)